Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HRH2 | P25021 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7353127 | 0.90 | LTA4H (0.58) | HRH3KCNH2 | |
| SCHEMBL21757629 | 0.86 | HRH3 (0.58) | HRH3HRH2KCNH2MEN1LMNA | |
| SCHEMBL21757618 | 0.85 | KDM4E (0.59) | HRH3HRH2KCNH2MEN1LMNA | |
| SCHEMBL21757567 | 0.82 | HRH3 (0.63) | HRH3HRH2KCNH2LMNA | |
| SCHEMBL30411052 | 0.81 | HRH3 (0.68) | HRH3ATML3MBTL1KCNH2MEN1 | |
| SCHEMBL30410433 | 0.80 | HRH3 (0.67) | HRH3ATML3MBTL1KCNH2MEN1 | |
| SCHEMBL30409879 | 0.80 | HRH3 (0.67) | HRH3ATML3MBTL1KCNH2MEN1 | |
| SCHEMBL30409990 | 0.80 | HRH3 (0.65) | HRH3ATML3MBTL1KCNH2MEN1 | |
| SCHEMBL30410512 | 0.78 | MEN1 (0.66) | HRH3ATML3MBTL1KCNH2MEN1 | |
| SCHEMBL30409967 | 0.78 | MEN1 (0.66) | HRH3ATML3MBTL1KCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215509-B1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC (US) | 2020-02-26 | — | — | EP | disclosed |